Context Therapeutics (NASDAQ:CNTX - Get Free Report) announced its earnings results on Thursday. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.01, reports.
Context Therapeutics Trading Up 0.2 %
CNTX traded up $0.00 on Friday, hitting $0.77. 60,567 shares of the company's stock traded hands, compared to its average volume of 389,861. The company's 50 day simple moving average is $0.85 and its 200-day simple moving average is $1.44. The firm has a market cap of $57.88 million, a price-to-earnings ratio of -0.85 and a beta of 2.06. Context Therapeutics has a one year low of $0.64 and a one year high of $2.75.
Analyst Ratings Changes
CNTX has been the topic of several research reports. Citizens Jmp raised Context Therapeutics to a "strong-buy" rating in a research report on Wednesday, January 8th. JMP Securities assumed coverage on Context Therapeutics in a research report on Wednesday, January 8th. They set an "outperform" rating and a $4.00 price objective on the stock. HC Wainwright reaffirmed a "buy" rating and set a $5.00 price objective on shares of Context Therapeutics in a research report on Friday. Finally, D. Boral Capital reaffirmed a "buy" rating and set a $9.00 price objective on shares of Context Therapeutics in a research report on Friday. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $6.17.
Read Our Latest Report on Context Therapeutics
Context Therapeutics Company Profile
(
Get Free Report)
Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
Read More
Before you consider Context Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Context Therapeutics wasn't on the list.
While Context Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
